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Fibromyalgia is considered a stress-related disorder, and hypo- as well as hyperactive stress systems (sympathetic nervous system
and hypothalamic-pituitary-adrenal axis) have been found. Some observations raise doubts on the view that alterations in these
stress systems are solely responsible for ﬁbromyalgia symptoms. Cumulative evidence points at dysfunctional transmitter systems
that may underlie the major symptoms of the condition. In addition, all transmitter systems found to be altered in ﬁbromyalgia
inﬂuence the body’s stress systems. Since both transmitter and stress systems change during chronic stress, it is conceivable that
both systems change in parallel, interact, and contribute to the phenotype of ﬁbromyalgia. As we outline in this paper, subgroups
of patients might exhibit varying degrees and types of transmitter dysfunction, explaining diﬀerences in symptomatoloy and
contributing to the heterogeneity of ﬁbromyalgia. The ﬁnding that not all ﬁbromyalgia patients respond to the same medications,
targeting dysfunctional transmitter systems, further supports this hypothesis.
1. Fibromyalgiaas a Stress-RelatedDisorder
Fibromyalgia is characterized by heightened pain percep-
tion, including widespread hyperalgesia, in particular to
deep-pressure stimuli, enhanced temporal summation, and
reduced pain-inhibiting eﬀects of heterotopic noxious stim-
u l a t i o n( o f t e nt e r m e dd i ﬀuse noxious inhibitory control,
DNIC) [1]. Fibromyalgia has often been described as a
stress-related disorder, and altered stress systems have been
viewed as causal for pain and other symptoms experienced
in this condition [2]. The body’s two stress systems, the
hypothalamic-pituitary-adrenal (HPA) axis and the sympa-
thetic nervous system, are indeed altered in ﬁbromyalgia [1];
however, results on the speciﬁc changes are heterogeneous.
Forbothsystems,h yper -aswellash ypoactivityinbasalfunc-
tioning and acute stress responses has been reported (e.g.,
[3–8]). Concerning the HPA axis, it has been suggested that
prolonged periods of stress associated with heightened basal
tone and exaggerated acute stress responses (hyperreactivity)
are followed by the development of a hyporeactive HPA axis,
thus potentially explaining inconsistent ﬁndings regarding
the HPA axis [9].
Stress increases the risk of developing ﬁbromyalgia, de-
pendent on diﬀerent predispositions (e.g., genetic makeup
and gender) [2]. However, it is still unclear which physiolog-
ical processes mediate the relationship between experienced
stress and the development of ﬁbromyalgia. Changes in the
autonomic and HPA stress systems are often considered as
such mediators, with chronic stress exposure altering the
functioning of these stress systems, causing ﬁbromyalgia
symptoms [2, 10]. In line with this view, the cardinal
symptom of the condition seems to be related to alterations
of the HPA axis: reported levels of clinical pain have been
shown to be associated with concentrations of corticotropin-
releasing hormone (CRH) in the cerebrospinal ﬂuid (CSF)
[11] and to salivary cortisol levels [12].
Nevertheless, prospective studies are scarce and available
results do not allow conclusions on causal relationships [13].
In addition, in contrast to pain, other prominent symptoms
associated with ﬁbromyalgia, such as fatigue, depressivity,2 Pain Research and Treatment
and perceived stress, appear not to be related to measures
o fH P Aa x i sf u n c t i o n[ 11, 12]. It is, therefore, conceivable
that ﬁbromyalgia symptoms are associated with altered
autonomic and HPA axis stress systems but that these altered
stress systems do not necessarily cause the symptoms. Stress-
related changes in other physiological systems, for example,
neurotransmitter systems, might be additionally involved in
symptom development. Further, stress-related changes in
such other systems may develop in parallel to changes in
the autonomic and HPA axis systems or even precede them,
thereby contributing to or causing ﬁbromyalgia symptoms.
In support of these considerations, some evidence sug-
gests that dysfunction of the body’s autonomic and HPA
axis stress systems are related to some of the risk factors for
developing ﬁbromyalgia, such as early-life stress [14] rather
thanplayingacausalroleinthepathogenesisofﬁbromyalgia.
For example, salivary cortisol levels in a cross-sectional
study were shown to diﬀer depending on the presence
or absence of early-life trauma (physical or sexual abuse)
but did not diﬀerentiate between ﬁbromyalgia patients and
healthy controls [12]. Similarly, CRH concentrations in the
CSF have been shown to be strongly related to the presence
or absence of early-life trauma (physical or sexual abuse)
[11]. Regarding the sympathetic system, evidence in healthy
volunteers suggests that reduced heart rate variability may be
a predisposing factor for the development of fatigue, pain,
and depressive symptoms rather than the underlying cause
of these symptoms [15].
2. DysfunctionalTransmitter
Systems in Fibromyalgia
Cumulative evidence points at alterations in neurotrans-
mitter systems in ﬁbromyalgia (see Figure 1), which is
interesting because the main symptoms of ﬁbromyalgia, that
is, heightened pain perception, fatigue, sleep disturbances,
and depressive as well as anxiety-related symptoms, are
closely linked to these neurotransmitters.
The key symptom and main diagnostic criterion for
ﬁbromyalgia is chronic widespread pain. Several neurotrans-
mitters and modulators are substantially involved in pain
processing. For example, central serotonin and noradrenalin
are important in endogenous pain inhibitory pathways [19,
20] and serotonin plays also an essential role in descending
pain facilitation via the 5HT3 receptor [21, 22]. Substance P
is a neuropeptide that is important for spinal nociception.
It coexists with the excitatory neurotransmitter glutamate in
primary nociceptive aﬀerents [23] and causes sensitization
of dorsal horn neurons [24, 25]. Not surprisingly, glutamate
itself plays an important role in nociception, as it has
excitatory and sensitizing eﬀects [26]. In addition, glutamate
hassomeinhibitoryeﬀectsindescendingpainpathways[21].
Although it has to be acknowledged that the exact eﬀects and
modulatory actions of these transmitters depend on receptor
subtypes and CNS site [21, 22], serotonin, noradrenalin,
substance P, and glutamate have been shown to be altered in
ﬁbromyalgia in ways that could explain patients’ increased
pain sensitivity. CNS levels of serotonin and noradrenalin
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Figure 1: Alterations in transmitter systems found in ﬁbromyalgia
patients in terms of increased or decreased activity and action of
drugs used in ﬁbromyalgia on these transmitters systems in terms
of activity increase or decrease. ∗T h ep o s i t i v ee ﬀect of naltrexone,
an opioid antagonist, on ﬁbromyalgia symptoms is suggested to be
mediated through disinhibiting eﬀects on HPA axis activity, rather
than by its eﬀect on the opioid system (cf. [16–18]).
appear to be lowered, indicated by decreased levels of
metabolites in the CSF and of serotonin and noradrenalin
in blood [27–30], possibly contributing to dysfunctional
descending pathways and resulting in attenuated descending
inhibition (cf. [31]). CSF concentrations of substance P and
glutamate have been repeatedly found to be increased in
ﬁbromyalgia patients [32–34]. With respect to glutamate,
proton magnetic resonance spectroscopy studies could show
that this neurotransmitter is elevated in pain processing
regions such as the insula, amygdala, and cingulate cortex
[35–39]. Supporting the hypothesis that a hyperactive glu-
tamate system contributes to increased pain sensitivity, and
maybe other symptoms of ﬁbromyalgia, elevated glutamate
levels in the insular cortex have been observed to be cor-
related with low pressure pain thresholds [39]a sw e l la sw i t h
high scores on the ﬁbromyalgia impact questionnaire (FIQ,
[40]) [37].
Similartoserotoninandnoradrenalin,dopamineactivity
has been demonstrated to be attenuated in ﬁbromyalgia (see
[41] for review): CSF levels of dopamine [28]a n dp r e s y n a p -
tic dopamine function are reduced (examined with positron
emission tomography (PET)) [42], and dopamine responses
to acute pain are diminished in ﬁbromyalgia patients [43].
Since inactivation of D2 receptors has been shown to
lead to hyperalgesia [44], these ﬁndings may suggest that
dysfunctional dopaminergic neurotransmission contribute
to patients’ pain symptomatology.
Particularly important for the endogenous control of
nociception are endogenous opioids, as they decrease trans-
mission of nociceptive signals in several pathways and
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to be increased in ﬁbromyalgia as indicated by increased
CSF and blood serum opioid levels [46], upregulation of
opioid receptors [47], and reduced cerebral mu-receptor
binding at rest (indicative of increased release) [48]. It is not
readily conceivable how an overactive opioid system would
contribute to ﬁbromyalgia symptoms. Indeed, elevated levels
of opioids might be a consequence of pain, rather than a
cause, since similar ﬁndings have been obtained in other
chronic pain conditions [49, 50]. Nevertheless, mu-opioid
receptor binding potentials have been found to be negatively
correlated with measures of aﬀective pain in ﬁbromyalgia
[48], perhaps explaining the emotional connotation of pain
in ﬁbromyalgia. Another important neurotransmitter of
antinociception is GABA [51], the main inhibitory neuro-
transmitter in the CNS. Although direct investigations are
not yet available, pharmacological studies have shown a
certain eﬀectiveness of GABAergic agents for pain, sleep,
and fatigue, suggesting that this inhibitory neurotransmitter
system might also be impaired in ﬁbromyalgia.
In addition to increasing pain sensitivity, alterations in
serotonin, noradrenalin, and substance P may contribute
to disturbances in sleep or mood in ﬁbromyalgia patients.
Serotonin and noradrenalin are strongly associated with
circadian rhythms (see [52] for review), and serotonin is
recognized as a mediator of deep sleep [53]. Moreover, a
deﬁcient serotonin system is strongly associated with major
depression [54]. Increased levels of intracerebral substance P
have been associated with increased anxiety-like behavior in
animals [55], and accordingly, NK1-receptor blockade (NK-
receptors are the receptors for substance P) is associated with
reduced anxiety [56].
3.The Role of AlteredTransmittersin
Stress Systems
Dysregulated neurotransmitter systems have been suggested
to play a role in the etiology and pathogenesis of stress-
related pathologies including ﬁbromyalgia (cf. [57, 58]).
For example, deﬁcient noradrenergic modulatory function
is hypothesized to increase the vulnerability to stress-related
pathology [58]. In line with this hypothesis, all of the neu-
rotransmitters systems found to be altered in ﬁbromyalgia
exert inﬂuences on the sympathetic nervous system or the
H P Aa x i ss t r e s ss y s t e m( s e e[ 52, 59]f o rr e v i e w ;s e eTable 1).
Serotonin and noradrenalin have been shown to have
a mainly excitatory inﬂuence on acute stress responses and
both are key in circadian rhythm of the HPA axis [52, 59–
61]. Dopamine has excitatory inﬂuences on the basal tone
of the HPA axis and enhances acute stress responses, as
demonstrated in various animal and human studies (e.g.,
[62–64]). Another excitatory neurotransmitter in CNS stress
circuits is glutamate even though glutamate is present also
in inhibitory stress circuits [52, 65–67]. It is hypothesized
that an optimal “glutamate tone” is required, whereby too
little or too much results in HPA activation [52]. GABA and
substance P both inhibit HPA axis functioning: they have a
tonic inhibitory inﬂuence on the HPA axis and terminate
acute HPA stress responses (GABA [68–70]; substance P
[59, 71, 72]). Evidence suggests that opioids diminish stress-
inducedautonomicstressresponses[57,73],butfortheHPA
axis, both inhibitory and excitatory eﬀects have been found
[74, 75], presumably depending on receptor subtypes and
type of stressor [74–76].
The transmitter disturbances observed in ﬁbromyalgia
could readily explain hyporeactivity of both stress systems,
as found in ﬁbromyalgia (see above; [1]). Transmitters that
regulatecircadianrhythmandenhanceacutestressresponses
such as serotonin, noradrenalin, and dopamine are reduced
in ﬁbromyalgia, while substance P, which inhibits basal tone
and acute responses of the HPA axis, is increased. Similarly,
opioids, which are increased in ﬁbromyalgia, inhibit acute
sympathetic and HPA axis stress responses.
In contrast, these transmitter aberrations cannot easily
explain a hyperactivity of the stress systems, which has
equally been shown in ﬁbromyalgia [1]. This might be
becausetheviewpresentedintheprecedingparagraphisvery
simplistic. The speciﬁc eﬀe c to fan e u r o t r a n s m i t t e rm a yb e
only weakly related to its global level (which is the measure
often obtained in human studies) but depends on factors
such as receptors subtype, brain region, concentration
relative to other neurochemicals, and the type of stressor.
For example, evidence suggests functional diﬀerences of
serotonin receptor subtypes in HPA axis regulation [61, 77],
and the modulatory function of serotonin appears to be
dependent on speciﬁc brain regions and stressors [60]. The
same has been suggested for dopamine [63, 78–80]a n d
glutamate [66, 81–84]. Similarly, the diﬀerential inhibitory
and excitatory eﬀects of opioids have been suggested to
be due to diﬀerent opioids acting through diﬀerent opioid
receptorsinadditiontoadependenceonstimulusconditions
[74–76].
The situation gets even more complicated if one takes
into account changes in neurotransmitter functioning due
to chronic stress that in turn aﬀect sympathetic and HPA
axis stress responses. Chronic stress leads to attenuated HPA
axis responses that are mediated by serotonergic neurotrans-
mission, in contrast to the serotonin-mediated increase of
acute HPA axis responses under normal conditions [52, 60,
61]. Noradrenalin release seems to be increased by chronic
stress through sensitized noradrenergic neurons, leading
to enhanced autonomic and HPA axis excitability [52, 58,
85–87]. In otherwise healthy organisms, the experience of
chronicstresshasbeendemonstratedtoresultinincreasedas
well as decreased dopaminergic activity depending on recep-
tor subtype and brain region [88]. In general, dopaminergic
responses to stressors seem to be enhanced after exposure
to chronic stress [78], which could lead to hyperreactive
stress systems, since these systems are excited by dopamine.
In accordance with increased levels of endogenous opioids
and substance P found in ﬁbromyalgia, opioids [57, 89]
and substance P [52, 90] have been found to be increased
in response to chronic stress, leading to an attenuation of
HPA axis reactivity. Results on changes of glutamate and
GABA systems due to chronic stress are not conclusive: some
glutamate [91–93]a n dG A B A[ 94–96] receptors subunits are
upregulated, while others are downregulated with chronic
stress depending on brain regions.4 Pain Research and Treatment
Table 1: Overview of the eﬀects of the neurotransmitter systems found to be altered in ﬁbromyalgia on HPA axis activity and the eﬀects
of drugs used in ﬁbromyalgia, targeting these transmitter systems, on HPA axis activity. Information on eﬀects on the sympathetic nervous
system is not included, because results are scarce. The speciﬁc eﬀect of the transmitters depends on diﬀerent aspects of HPA axis activity,
that is, basal tone and circadian rhythm or acute stress responses. In addition, under conditions of chronic stress, the transmitter eﬀects
on the HPA axis are often altered. The table represents a simplistic summary of the evidence found on transmitter actions on HPA axis
activity. Despite a vast number of studies, the precise mechanisms of neurotransmitters on HPA axis functioning remain only incompletely
understood [52]; transmitter actions depend on receptor subtypes, brain regions, and type of stressor.
Transmitter system
Eﬀect on HPA axis activity in terms of HPA axis activity under chronic stress∗
basal tone and circadian
rhythm acute stress responses Eﬀe c to fd r u g so n
HPA axis activity∗
Serotonin excitatory (↑)a n d
inhibitory (↓) excitatory (↑) inhibitory (↓) excitatory (↑)a n d
inhibitory (↓)
Noradrenalin excitatory (↑)a n d
inhibitory (↓) excitatory (↑) excitatory (↑) excitatory (↑)a n d
inhibitory (↓)
Dopamine excitatory (↑)e x c i t a t o r y ( ↑) excitatory (↑) ?
Opioids excitatory (↑) inhibitory (↓) inhibitory (↓) excitatory (↑)
Glutamate ? excitatory (↑) ? excitatory (↑)a n d
inhibitory (↓)
GABA inhibitory (↓) inhibitory (↓) excitatory (↑) ?
Substance P inhibitory (↓) inhibitory (↓) inhibitory (↓) ?
∗Chronic stress as well as drugs have diﬀerential eﬀects on basal tone, circadian rhythm, and acute responses to stress but most studies do not diﬀerentiate
these aspects. Accordingly, this table does not diﬀerentiate in these instances.
These diverse results strongly suggest that chronic stress
does not aﬀect transmitters and stress systems uniformly.
In fact, the diversity of the results on chronic stress-
induced changes in transmitter functioning favoring in some
instances hypoactive, and in other instances, hyperactive
stress systems are reminiscent of the range that is found
regarding the activity of the stress systems in ﬁbromyalgia
patients.Soperhapswhetherthesympatheticnervoussystem
and/or the HPA axis is hyper- or hypoactive in a given
individual depends on the ratio of dysfunctions in diﬀerent
transmitter systems, rather than absolute transmitter levels.
For example, hyperactivity of the HPA axis could be associ-
ated with alterations in glutamate and opioids that are more
pronounced than changes in serotonin, noradrenalin, and
dopamine. The diﬀerent transmitter dysfunctions may also
change as a function of time, which could then contribute
to stress systems alterations that are not constant over
time (cf. [9]). Individual patients might exhibit varying
degrees and types of transmitter dysfunction, and indeed,
ﬁbromyalgia patients are recognized to be a heterogeneous
group. Accordingly, categorization of ﬁbromyalgia patients
into subgroups has been suggested. Generally, ﬁbromyalgia
patients are subdivided into a group with a predominant
pain phenotype (strong hyperalgesia) without or only mild
related psychopathological ﬁndings and into patients with
(major) depression although diﬀerent ways of categorizing
and diﬀerent numbers of subgroups have been suggested
[97–99]. In any case, most studies on dysfunctional neuro-
transmitters as well as on stress systems in ﬁbromyalgia have
not taken any subcategorization into account even though
it seems reasonable to assume that these subgroups diﬀer
not only with respect to their symptoms but also regarding
the mechanisms underlying the condition. Considering
that transmitter alterations seem to be strongly related to
symptoms,itseemsconceivablethatsubgroupsofﬁbromyal-
gia patients are characterized by diﬀerent transmitter alter-
ations and that the ratio of dysfunctions in diﬀerent trans-
mitter systems varies between subgroups. The observation
that not all ﬁbromyalgia patients respond to the same
medications (Figure 1). Further supports the notion that
subgrouping might be important in studies on ﬁbromyalgia.
4. Pharmacological Interventionsin
FibromyalgiaTargeting Dysfunctional
Transmitter Systems
Pharmacological compounds that raise serotonin and nora-
drenalin concentrations such as tricyclic antidepressants
(TCAs) and dual reuptake inhibitors of serotonin and nora-
drenalin are relatively eﬀective treatments of ﬁbromyalgia,
improving mainly pain, sleep, and fatigue although not
in all patients (see [100–102] for review). Interestingly,
the beneﬁcial eﬀects of these medications are independent
of eﬀects on mood (e.g., [103, 104]). Selective serotonin
reuptake inhibitors (SSRIs) are less eﬀective compared
to TCAs and dual reuptake inhibitors. Moreover, newer
SSRIs (e.g., citalopram), which are even more selective for
serotonin reuptake inhibition, appearto be even less eﬀective
compared to older SSRIs (e.g., ﬂuoxetine and paroxetine)
[101]. Taken together, reuptake inhibition of noradrenalin
seemstobemoreimportantcomparedtoreuptakeinhibition
of serotonin. Therefore, it would be interesting to investigate
the eﬀects of selective noradrenalin reuptake inhibitors
(e.g., reboxetine) on ﬁbromyalgia symptoms, which has not
yet been done to the best of our knowledge. Moreover,
antidepressants such as TCAs or SSRIs, dampen HPA axis
activity in patients with major depression [105]. If this wasPain Research and Treatment 5
also true in patients with ﬁbromyalgia, another factor for the
choice of medication would be the HPA axis activity status of
an individual patient.
A very interesting ﬁnding is that 5-HT3 receptor antago-
nists are eﬀective in ﬁbromyalgia patients with a primary
painphenotype(withoutdepression)butnotinﬁbromyalgia
patients with depression [97]. 5-HT3 antagonists act antihy-
peralgesic probably through a reduction of descending pain
facilitation [22]. The ﬁnding that some ﬁbromyalgia patients
respond to 5-HT3 antagonists does not necessarily ﬁt with
the ﬁnding of decreased serotonin activity in ﬁbromyalgia.
So, perhaps ﬁbromyalgia patients with a primary pain
phenotype, who respond to 5-HT3 antagonists, do not have
decreased serotonin levels and only those in whom depres-
sive symptoms dominate the clinical picture would show
decreased serotonin levels when subgrouped. However, one
has to be cautious with this hypothesis, because serotonin
concentrations could potentially vary across diﬀerent CNS
sites.
Glutamate and substance P disturbances in ﬁbromyalgia
might be targeted by pregabalin. Pregabalin binds to the
α2δ subunit of voltage-dependent calcium channels and
decreases the release of a variety of neurotransmitters,
including glutamate and substance P [106, 107]b yr e d u c -
ing the calcium inﬂux into nerve terminals. Pregabalin is
eﬀective particularly for pain and sleep. Interestingly, only
small or no eﬀects on anxiety symptoms have been found
in ﬁbromyalgia [108–112] although pregabalin is known to
haveanxiolyticeﬀects[113]andisapprovedbytheEuropean
Union for the treatment of anxiety disorders.
Other pharmacological treatments have been tested in
ﬁbromyalgia patients but evidence is weaker [100]. Ketamine
is an interesting molecule: typically conceived as a NMDA
receptor antagonist, it has recently been demonstrated to
act mainly as a D2 dopamine receptor agonist in low doses
[114]. Such low doses lead to reductions in experimen-
tal and clinical pain in approximately half of the tested
ﬁbromyalgia patients [115–117]. A study on the NMDA
receptorantagonistdextromethorphanfailedtodemonstrate
positive eﬀects on experimental pain in ﬁbromyalgia patients
[118], suggesting that the beneﬁcial eﬀects of ketamine
might indeed be related to its dopaminergic properties. The
eﬀects of ketamine on the HPA axis vary: while high doses
consistently increase HPA axis activity, doses comparable to
those used in ﬁbromyalgia have been found to enhance or
dampen eﬀects HPA axis functioning (e.g., [119–121]).
Interestingly, naltrexone, an opioid antagonist, has
shown some beneﬁcial eﬀect on fatigue and perceived stress
in ﬁbromyalgia patients [122]. Since naltrexone disinhibits
HPA activity [16–18], it could be postulated that it might be
particular eﬀective in patients with low HPA axis activity and
in whom fatigue is the predominant symptom rather than
pain.
Disturbances of GABAergic neurotransmission have not
yet been directly investigated in ﬁbromyalgia. Nevertheless, a
certain eﬀectiveness of sodium oxybate (γ-hydroxybutyrate)
(e.g., [123–125]), which acts as a GABAB receptor agonist,
benzodiazepines [126], which enhance the eﬀect of GABA,
and (nonbenzodiazepine) hypnotics [127–129], which act
as GABAA receptor agonists, for pain, sleep, and fatigue
has been observed. Benzodiazepines and hypnotics that act
at GABAA receptors dampen HPA axis activity (e.g., [130–
133]). Interestingly, zolpidem, which acts selectively at the
GABAA α1 receptor subunit, has been shown to enhance
H P Aa x i sa c t i v i t y[ 131, 132]. Presumably, this diﬀerential
eﬀect depends on the drug’s eﬀect on a speciﬁc GABA
receptor subunit and the net eﬀect of the nonselective
drugs results from by action on diﬀerent receptor subunits
[131, 132]. It would be interesting to investigate whether
the eﬀects of selective and nonselective drugs targeting
GABAergic neurotransmission are diﬀerent in ﬁbromyalgia
patient subgroups with hypo- or hyperactive stress systems.
5. Stress-InducedChanges in
TransmitterSystemsasa Pathogenic
Factor in Fibromyalgia?
Because transmitter changes seem to be closely related to
ﬁbromyalgia symptoms and could, at least partly, explain
alterations observed in the HPA axis as well as the sym-
pathetic system, dysregulated neurotransmitter systems may
play a pathogenic role in ﬁbromyalgia (cf. [57, 58]). Indeed,
chronic stress induces changes in relevant neurotransmitters,
as discussed above. In this theoretical framework, stress-
induced changes in transmitter systems would cause pain as
wellasothersymptoms in ﬁbromyalgiaand contributeto the
observed changes in the sympathetic as well as HPA stress
system. In addition, chronic stress also directly modiﬁes
the HPA axis and the autonomic nervous system, and the
stress systems are likely to inﬂuence the transmitter systems.
Consider, for example, substance P: chronic stress leads
to an increase in substance P [52, 90] and can cause a
hyporeactivity of the HPA axis. But because substance P
itself inhibits the HPA axis, the causal relationship remains
unclear. Diﬀerent scenarios are conceivable: the ﬁrst one is,
the “serial stress system-based view” in which changes in the
functioning of the autonomic and HPA axis stress systems,
as a result of chronic stress, cause ﬁbromyalgia symptoms
and alter transmitter systems. In this scenario, changes in the
stress systems precede and cause ﬁbromyalgia symptoms and
dysfunctionaltransmittersystems,consideringdysfunctional
transmitters systems not as causally relevant for the patho-
genesis of ﬁbromyalgia. The second scenario is, the “serial
transmitter-based view” in which changes in transmitter
functioning, as a result of chronic stress, cause ﬁbromyalgia
symptoms and alter autonomic and HPA axis stress systems.
In this second scenario, dysfunctional stress systems are
not considered as causally relevant for the pathogenesis
of ﬁbromyalgia in that dysfunctional transmitter systems
precede and cause ﬁbromyalgia symptoms and altered stress
systems. Lastly, we have the “parallel view” in which chronic
stress is considered to cause dysfunctional transmitter as well
as autonomic andHPA axis stress systemsin parallel. Neither
changes in transmitter systems nor in stress systems precede
each other, but changes in the systems interact and both
dysfunctional transmitter and stress systems ﬁnally cause
ﬁbromyalgia symptoms.6 Pain Research and Treatment
The current evidence does not conclusively favor one
model. Longitudinal studies in ﬁbromyalgia that track the
d e v e l o p m e n to fd i s t u r b a n c e si nt r a n s m i t t e r sa sw e l la ss t r e s s
systems over time would be important in order to test
these models. Further, any study on the topic is likely
to substantially beneﬁt from subcategorizing ﬁbromyalgia
patients. Similarly, treatment studies should investigate well-
deﬁned subgroups of patients, ideally selected based on
speciﬁc biochemical alterations that are hypothesized to
be impacted by the speciﬁc therapy. Although—or maybe
because—thisisalong“to-do”list,ithastobeacknowledged
that research in recent years has already made great advances
in uncovering CNS alterations and potential mechanisms
that might contribute to the complex clinical phenomenon
of ﬁbromyalgia.
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